Corline Biomedical AB - Asset Resilience Ratio

Latest as of September 2025: 7.07%

Corline Biomedical AB (CLBIO) has an Asset Resilience Ratio of 7.07% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CLBIO current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Skr5.82 Million

≈ $626.11K USD Cash + Short-term Investments

Total Assets

Skr82.31 Million

≈ $8.86 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Corline Biomedical AB's Asset Resilience Ratio has changed over time. See CLBIO book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Corline Biomedical AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Corline Biomedical AB.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr5.82 Million	7.07%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr5.82 Million	7.07%

Asset Resilience Insights

Limited Liquidity: Corline Biomedical AB maintains only 7.07% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Corline Biomedical AB Industry Peers by Asset Resilience Ratio

Compare Corline Biomedical AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fortress Biotech Inc NASDAQ:FBIO	Biotechnology	11.59%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Apellis Pharmaceuticals Inc NASDAQ:APLS	Biotechnology	0.58%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
BioArctic AB (publ) ST:BIOA-B	Biotechnology	72.35%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.73%

Annual Asset Resilience Ratio for Corline Biomedical AB (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Corline Biomedical AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	18.64%	Skr17.67 Million ≈ $1.90 Million	Skr94.76 Million ≈ $10.20 Million	+1.65pp
2023-12-31	16.99%	Skr17.01 Million ≈ $1.83 Million	Skr100.11 Million ≈ $10.77 Million	-8.76pp
2022-12-31	25.75%	Skr26.21 Million ≈ $2.82 Million	Skr101.78 Million ≈ $10.95 Million	-15.20pp
2021-12-31	40.95%	Skr41.63 Million ≈ $4.48 Million	Skr101.66 Million ≈ $10.94 Million	+26.09pp
2020-12-31	14.86%	Skr8.66 Million ≈ $932.28K	Skr58.28 Million ≈ $6.27 Million	-20.99pp
2019-12-31	35.85%	Skr22.86 Million ≈ $2.46 Million	Skr63.75 Million ≈ $6.86 Million	-8.09pp
2018-12-31	43.94%	Skr27.64 Million ≈ $2.97 Million	Skr62.91 Million ≈ $6.77 Million	+11.16pp
2017-12-31	32.78%	Skr16.86 Million ≈ $1.81 Million	Skr51.43 Million ≈ $5.53 Million	+4.03pp
2016-12-31	28.74%	Skr11.86 Million ≈ $1.28 Million	Skr41.27 Million ≈ $4.44 Million	--

pp = percentage points

About Corline Biomedical AB

ST:CLBIO Sweden Biotechnology

Market Cap

$42.30 Million

Skr393.08 Million SEK

Market Cap Rank

#22495 Global

#416 in Sweden

Share Price

Skr16.05

Change (1 day)

-0.62%

52-Week Range

Skr9.66 - Skr21.20

All Time High

Skr28.20